A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 900 participants.
Also called NCT07662135
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 900 participants
- Sponsor
- Registry
-
NCT07662135 -
2025-523940-12-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Bulgaria, China, Denmark, Germany, India, Japan, Malaysia, Mexico, Spain, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT07662135. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-07-13 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Acronym
- Eluminate-4
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes With Chronic Kidney Disease
- Intervention (Drug)
- Elecoglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07662135- Content hash
c275863d028687e532b7b84389db172122d0b444e7711bec286ceb61810b72be